{"title":"New product intros [avapritinib, benzhydrocodone hydrochloride/acetaminophen (new combination), crizanlizumab-tmca (first-in-class), enfortumab vedotin-ejfv (first-in-class), givosiran (first-in-class), lasmiditan succinate (first-in-class), semaglutide (new indication), ubrogepant]","authors":"","doi":"10.1358/dot.2020.56.2.3138014","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2020.56.2.3138014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
新产品介绍[阿伐替尼、盐酸苯氢可酮/对乙酰氨基酚(新组合)、克里赞利单抗-tmca(同类首创)、安替妥单抗-ejfv(同类首创)、吉伏昔兰(同类首创)、琥珀酸拉斯米坦(同类首创)、西马鲁肽(新适应症)、增稠剂]
本文章由计算机程序翻译，如有差异，请以英文原文为准。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
